Icahn School of Medicine at Mount Sinai

Yale University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Click Therapeutics, Inc.

Dennis S Charney

John H Krystal

Brian M Iacoviello

Carlos A Zarate

Husseini K Manji

Adriana Feder

Sanjay J Mathew

John P Seibyl

The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder.

Method of treating post-traumatic stress disorder

Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed. Each expression image is independently associated with an expression. The successive display of images is construed as a tiled series of expression image subsets, each consisting of N expression images. Upon completion of the display of each respective subset, the user is challenged as to whether the first and the last images in the respective subset exhibit the same emotion. A score is determined for the respective subset based on whether the subject learned to respond correctly. The number of images in each subset is adjusted to a new number based on these scores. A treatment regimen is prescribed to the subject for the psychiatric disorder based at least in part on the scores.

Systems and methods for treating a psychiatric disorder

The present disclosure relates to systems and methods for accessing a data structure including a subject identifier identifying a subject and a subject connectivity value derived from at least one of a scan or test provided to the subject, the subject connectivity value representing a magnitude of a connection associated with at least one sub-processing region of a nervous system of the subject; comparing the subject connectivity value to a connectivity threshold value to determine a classification of the subject; determining that the subject connectivity value exceeds the connectivity threshold value, storing in the data structure, an association between the subject identifier and a first classification value corresponding to a first classification or determining that the subject connectivity value is less than the connectivity threshold value, and storing in the data structure, an association between the subject identifier and a second classification value corresponding to a second classification.

Systems and methods for processing connectivity values between sub-processing regions

The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.

Method for treating post-traumatic stress disorder

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (&#x3e;2 years).

Intranasal administration of ketamine to treat depression

Methods for treating suicidal ideation

Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.

Growing community of inventors

New York, NY, United States of America

Dennis S Charney